Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
"Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1): A Double-blind, Randomised, Phase 3 Trial." The Lancet, 2021, 398(10295):143-155
We know you might be skeptical
The severity of symptoms can also differ
Beyond glycemic control, tirzepatide affects appetite regulation through central nervous system pathways
Feb 22, 2026 You are sitting at the highest dose of tirzepatide
As your appetite changes, your eating habits might shift toward foods higher in sulphur increasing the chances of these unpleasant burps
US$ 25.06
US$ 20.36
US$ 21.04
US$ 28.61
